ArticleCancer informatics2026
Prospective Breast Cancer Biomarkers Identified Using miR-526b-Driven Metabolic Alterations.
Article in Cancer informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Breast cancer is a heterogeneous disease driven by dysregulated cellular processes, including altered metabolic pathways. The oncogenic microRNA miR-526b influences several cancer hallmark phenotypes and holds promise as a plasma biomarker. Given miR-526b's role in metabolic regulation, we have decided Methods: We analyzed mRNA expression of these 4 metabolic markers in breast cancer tissue biopsies and plasma samples from patients and disease-free controls, using publicly available datasets and RT-qPCR validation. Diagnostic performance was evaluated using univariate and multivariate logistic regression and LASSO regression modeling. The potential of combining Results: Individually, none of the metabolic markers demonstrated sufficient sensitivity or specificity as plasma biomarkers. However, combining markers via logistic and LASSO regression improved classification performance. Conclusions: Our study validates the potential of miR-526b-regulated metabolic genes as complementary breast cancer biomarkers. While
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.